» Articles » PMID: 23463953

Risk Factors in Cardiovascular Disease in Systemic Lupus Erythematosus

Overview
Date 2013 Mar 8
PMID 23463953
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is a chronic and multisystemic autoimmune disorder which predominantly affecting women. The most common cause of death in SLE patients affected by disease for more than 5 years is cardiovascular disease (CVD). Epidemiological observations suggest that, together with classical conventional risk factors, other mechanisms (non-conventional/disease-specific factors) promote accelerated atherosclerosis in inflammatory diseases like SLE. Traditional CVD risk factors included age, hypertension, diabetes mellitus, dyslipidemia, previous vascular event defined as previous history of cerebrovascular accidents or ischemic heart disease, menopause and smoking. The nontraditional factors presents in SLE are disease-specific like renal disease manifestation as Lupus nephritis (LN), presence of pro-inflammatory cytokines, some of inflammatory mediators, antiphospholipid antibodies, anti-oxLDL antibodies, corticosteroid uses and cumulative dose of glucocorticoids. We will review traditional and non-traditional risk factors associated with CVD in SLE patients.

Citing Articles

Predicting the risk of cardiovascular and cerebrovascular event in systemic lupus erythematosus: a Chinese SLE treatment and research group study XXVI.

Huang C, Li Y, Wang Z, Lin S, Zhao J, Wang Q RMD Open. 2024; 10(3).

PMID: 39313305 PMC: 11418496. DOI: 10.1136/rmdopen-2024-004425.


Proposal of a novel cardiovascular risk prediction score in lupus nephritis.

Molnar A, Juha M, Bulajcsik K, Tabak A, Tisler A, Ledo N Front Immunol. 2024; 15:1405463.

PMID: 39114663 PMC: 11305119. DOI: 10.3389/fimmu.2024.1405463.


Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis.

Wong C, Ma B, Zhang D, Cheung W, Chan T, Yap D Lupus Sci Med. 2024; 11(1).

PMID: 38519060 PMC: 10961538. DOI: 10.1136/lupus-2024-001152.


Thyroid Hormones and Cardiometabolic Risk Factors in Saudi Women with Polycystic Ovary Syndrome: A Cross-Sectional Study.

Saeed W, Alsehli F Int J Womens Health. 2023; 15:1197-1203.

PMID: 37525744 PMC: 10387246. DOI: 10.2147/IJWH.S405942.


Rosuvastatin treatment alone cannot alleviate lupus in murine model: a pilot study.

Baek W, Lee S, Lee S, Suh C J Rheum Dis. 2023; 30(3):198-203.

PMID: 37476679 PMC: 10351369. DOI: 10.4078/jrd.2023.0021.


References
1.
Roman M, Shanker B, Davis A, Lockshin M, Sammaritano L, Simantov R . Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med. 2003; 349(25):2399-406. DOI: 10.1056/NEJMoa035471. View

2.
Vaarala O, Manttari M, Manninen V, Tenkanen L, Puurunen M, Aho K . Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995; 91(1):23-7. DOI: 10.1161/01.cir.91.1.23. View

3.
Medzhitov R . Origin and physiological roles of inflammation. Nature. 2008; 454(7203):428-35. DOI: 10.1038/nature07201. View

4.
Yang L, Tao J, Tang X, Wang Y, He X, Xu G . Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients. J Eur Acad Dermatol Venereol. 2011; 26(1):95-101. DOI: 10.1111/j.1468-3083.2011.04211.x. View

5.
Ross R . Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2):115-26. DOI: 10.1056/NEJM199901143400207. View